Great Lakes Advisors LLC Makes New $1.70 Million Investment in Hims & Hers Health, Inc. $HIMS

Great Lakes Advisors LLC bought a new position in Hims & Hers Health, Inc. (NYSE:HIMS) in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm bought 30,018 shares of the company’s stock, valued at approximately $1,703,000.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Geode Capital Management LLC boosted its holdings in Hims & Hers Health by 1.5% in the 2nd quarter. Geode Capital Management LLC now owns 4,746,081 shares of the company’s stock worth $236,622,000 after buying an additional 71,593 shares during the period. Invesco Ltd. raised its holdings in Hims & Hers Health by 502.2% during the 2nd quarter. Invesco Ltd. now owns 2,552,405 shares of the company’s stock valued at $127,237,000 after acquiring an additional 2,128,587 shares during the period. Clear Street LLC purchased a new stake in shares of Hims & Hers Health during the second quarter worth $83,582,000. Norges Bank purchased a new stake in shares of Hims & Hers Health during the second quarter worth $78,464,000. Finally, State of Michigan Retirement System boosted its holdings in shares of Hims & Hers Health by 84.9% in the second quarter. State of Michigan Retirement System now owns 1,379,100 shares of the company’s stock worth $68,748,000 after acquiring an additional 633,300 shares during the period. Institutional investors own 63.52% of the company’s stock.

Analyst Ratings Changes

A number of analysts recently issued reports on HIMS shares. Weiss Ratings reiterated a “hold (c)” rating on shares of Hims & Hers Health in a research note on Monday, December 29th. BTIG Research reiterated a “buy” rating and set a $85.00 price target on shares of Hims & Hers Health in a research report on Tuesday, November 4th. Barclays assumed coverage on shares of Hims & Hers Health in a report on Monday, December 8th. They issued an “overweight” rating and a $48.00 price target on the stock. Zacks Research cut shares of Hims & Hers Health from a “hold” rating to a “strong sell” rating in a research note on Monday, January 19th. Finally, UBS Group set a $32.00 target price on shares of Hims & Hers Health in a report on Tuesday, November 4th. One research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, nine have given a Hold rating and four have assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $44.54.

Insider Activity at Hims & Hers Health

In other news, CFO Oluyemi Okupe sold 9,067 shares of the stock in a transaction dated Tuesday, January 20th. The stock was sold at an average price of $30.34, for a total transaction of $275,092.78. Following the transaction, the chief financial officer directly owned 91,617 shares in the company, valued at approximately $2,779,659.78. This represents a 9.01% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, COO Michael Chi sold 13,750 shares of the firm’s stock in a transaction dated Wednesday, December 17th. The shares were sold at an average price of $36.71, for a total value of $504,762.50. Following the transaction, the chief operating officer directly owned 305,161 shares in the company, valued at approximately $11,202,460.31. This represents a 4.31% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 131,974 shares of company stock worth $4,763,800 in the last three months. 13.71% of the stock is owned by insiders.

Hims & Hers Health Stock Down 9.1%

Shares of NYSE HIMS opened at $27.15 on Friday. The company has a current ratio of 1.88, a quick ratio of 1.64 and a debt-to-equity ratio of 1.67. The business has a 50-day moving average of $34.34 and a 200-day moving average of $44.31. The firm has a market capitalization of $6.18 billion, a price-to-earnings ratio of 50.28, a PEG ratio of 4.92 and a beta of 2.37. Hims & Hers Health, Inc. has a 12 month low of $23.97 and a 12 month high of $72.98.

Hims & Hers Health (NYSE:HIMS) last announced its earnings results on Monday, November 3rd. The company reported $0.06 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.09 by ($0.03). The company had revenue of $598.98 million for the quarter, compared to the consensus estimate of $578.99 million. Hims & Hers Health had a net margin of 6.05% and a return on equity of 24.67%. The company’s revenue for the quarter was up 49.2% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.32 earnings per share. Sell-side analysts expect that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current fiscal year.

Hims & Hers Health declared that its Board of Directors has approved a share repurchase plan on Monday, November 17th that allows the company to buyback $250.00 million in outstanding shares. This buyback authorization allows the company to purchase up to 3% of its stock through open market purchases. Stock buyback plans are typically a sign that the company’s board of directors believes its shares are undervalued.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.